Trial Profile
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
- 09 Jan 2017 Results of population pharmacokinetic analysis (n=600) from one phase II clinical trial (NCT00918255) and two phase III clinical trials (NCT01468207 and NCT01468233) assessing the effects of potential covariates on adalimumab pharmacokinetics, published in the Clinical Pharmacokinetics journal.
- 21 Oct 2013 New trial record